Financials Fermentalg

Equities

Market Closed - Euronext Paris Other stock markets 11:37:26 2024-04-26 am EDT			5-day change	1st Jan Change
0.565 ^EUR	-0.18%		-5.52%	+87.09%

Apr. 12	Fermentalg: transfer to Euronext Growth on April 16	CF
Apr. 04	Fermentalg SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024
Capitalization ¹	42.4	27.76	36.29	124	60.87	23.28	23.28
Enterprise Value (EV) ¹	38.27	31.29	40.29	107.6	55.99	12.44	36.58
P/E ratio	-5.28 x	-1.59 x	-4.52 x	-16.4 x	-6.35 x	-0.94 x	-2.57 x
Yield	-	-	-	-	-	-	-
Capitalization / Revenue	172 x	14.7 x	16.5 x	22 x	7.96 x	3.07 x	2.38 x
EV / Revenue	156 x	16.6 x	18.3 x	19.1 x	7.32 x	3.07 x	3.73 x
EV / EBITDA	-8.52 x	-4.91 x	-8.28 x	-21 x	-8.64 x	-1.44 x	-5.23 x
EV / FCF	-4.19 x	-3.11 x	-	-	-	-3.52 x	-3.36 x
FCF Yield	-23.9%	-32.2%	-	-	-	-28.4%	-29.8%
Price to Book	1.24 x	1.53 x	1.8 x	2.64 x	-	0.9 x	1.38 x
Nbr of stocks (in thousands)	17,098	17,976	25,095	39,870	39,968	41,195	41,195
Reference price ²	2.480	1.544	1.446	3.110	1.523	0.5650	0.5650
Announcement Date	3/11/19	4/1/20	4/16/21	4/22/22	4/20/23	4/4/24	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024
Net sales ¹	0.246	1.888	2.205	5.647	7.648	4.058	9.8
EBITDA ¹	-4.494	-6.372	-4.864	-5.133	-6.482	-8.654	-7
EBIT ¹	-7.121	-13.61	-6.18	-5.856	-9.03	-11.81	-10.2
Operating Margin	-2,894.72%	-720.97%	-280.27%	-103.7%	-118.07%	-290.98%	-104.08%
Earnings before Tax (EBT)	-8.091	-17.29	-6.878	-6.85	-	-	-
Net income ¹	-8.147	-17.4	-6.917	-6.85	-9.874	-14.1	-10.9
Net margin	-3,311.79%	-921.61%	-313.7%	-121.3%	-129.11%	-347.36%	-111.22%
EPS ²	-0.4700	-0.9700	-0.3200	-0.1900	-0.2400	-0.3200	-0.2200
Free Cash Flow ¹	-9.13	-10.07	-	-	-	-7.3	-10.9
FCF margin	-3,711.38%	-533.16%	-	-	-	-182.5%	-111.22%
FCF Conversion (EBITDA)	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-
Announcement Date	3/11/19	4/1/20	4/16/21	4/22/22	4/20/23	4/4/24	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024
Net Debt ¹	-	3.54	4	-	-	2.4	13.3
Net Cash position ¹	4.13	-	-	16.4	4.88	-	-
Leverage (Debt/EBITDA)	-	-0.5549 x	-0.823 x	-	-	-0.3243 x	-1.9 x
Free Cash Flow ¹	-9.13	-10.1	-	-	-	-7.3	-10.9
ROE (net income / shareholders' equity)	-21.4%	-46.8%	-49.6%	-28.2%	-22.2%	-36.3%	-54.5%
ROA (Net income/ Total Assets)	-	-	-	-	-	-	-
Assets ¹	-	-	-	-	-	-	-
Book Value Per Share ²	2.010	1.010	0.8000	1.180	-	0.6300	0.4100
Cash Flow per Share ²	-0.2400	-0.3800	-0.3900	-0.2100	-0.2000	-0.2000	-0.1900
Capex ¹	5.02	3.28	-	-	-	3.8	1.5
Capex / Sales	2,040.65%	173.83%	-	-	-	95%	15.31%
Announcement Date	3/11/19	4/1/20	4/16/21	4/22/22	4/20/23	4/4/24	-

¹EUR in Million²EUR

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.565 EUR

Average target price

0.5 EUR

Spread / Average Target

-11.50%

	1st Jan change	Capi.
FERMENTALG	+87.09%	24.85M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B